A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently needed. New bispecific antibody (bsAb) formats...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio-Pérez, Laura, Lázaro-Gorines, Rodrigo, Harwood, Seandean L., Compte, Marta, Navarro, Rocío, Tapia-Galisteo, Antonio, Bonet, Jaume, Blanco, Belén, Lykkemark, Simon, Ramírez-Fernández, Ángel, Ferreras-Gutiérrez, Mariola, Domínguez-Alonso, Carmen, Díez-Alonso, Laura, Segura-Tudela, Alejandro, Hangiu, Oana, Erce-Llamazares, Ainhoa, Blanco, Francisco J., Santos, Cruz, Rodríguez-Peralto, José L., Sanz, Laura, Álvarez-Vallina, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10128431/
https://www.ncbi.nlm.nih.gov/pubmed/37114242
http://dx.doi.org/10.1080/2162402X.2023.2205336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10128431/
https://www.ncbi.nlm.nih.gov/pubmed/37114242
http://dx.doi.org/10.1080/2162402X.2023.2205336

Ejemplares similares